{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Exposure+to+healthy+labels+only&page=3",
    "query": {
      "intervention": "Exposure to healthy labels only",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 53,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Exposure+to+healthy+labels+only&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Exposure+to+healthy+labels+only&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-06T11:33:57.780Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06100913",
      "title": "Immunology of Ebola Vaccine",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ebola Virus Disease"
      ],
      "interventions": [
        {
          "name": "Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Deuterium Labeled Water",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2024-08-06",
      "completion_date": "2027-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-22",
      "last_synced_at": "2026-10-06T11:33:57.780Z",
      "location_count": 2,
      "location_summary": "Decatur, Georgia • St Louis, Missouri",
      "locations": [
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06100913"
    },
    {
      "nct_id": "NCT00914511",
      "title": "A Pharmacokinetic Study of Avanfil in Healthy Young Male Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Avanfil ADME",
        "Semen Exposure",
        "Sperm Function"
      ],
      "interventions": [
        {
          "name": "avanafil 200mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VIVUS LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 32,
      "start_date": "2009-05",
      "completion_date": "2009-06",
      "has_results": false,
      "last_update_posted_date": "2011-01-07",
      "last_synced_at": "2026-10-06T11:33:57.780Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00914511"
    },
    {
      "nct_id": "NCT00582504",
      "title": "Safety and Immunogenicity Study of the Venezuelan Equine Encephalomyelitis Vaccine",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Venezuelan Equine Encephalomyelitis"
      ],
      "interventions": [
        {
          "name": "VEE TC-83",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 500,
      "start_date": "2007-09",
      "completion_date": "2022-06",
      "has_results": false,
      "last_update_posted_date": "2021-02-11",
      "last_synced_at": "2026-10-06T11:33:57.780Z",
      "location_count": 1,
      "location_summary": "Fort Deterick, Maryland",
      "locations": [
        {
          "city": "Fort Deterick",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00582504"
    },
    {
      "nct_id": "NCT03872596",
      "title": "Trial to Assess the Bioavailability of Quetiapine Versus Seroquel® in Subjects With Schizophrenia or Bipolar Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bipolar Disorder",
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Seroquel IR 300mg",
          "type": "DRUG"
        },
        {
          "name": "Seroquel IR 25mg",
          "type": "DRUG"
        },
        {
          "name": "Quetiapine Formulation A 300mg",
          "type": "DRUG"
        },
        {
          "name": "Quetiapine Formulation B 300mg",
          "type": "DRUG"
        },
        {
          "name": "Quetiapine Formulation 25mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 58,
      "start_date": "2019-03-27",
      "completion_date": "2019-11-27",
      "has_results": false,
      "last_update_posted_date": "2020-09-02",
      "last_synced_at": "2026-10-06T11:33:57.780Z",
      "location_count": 1,
      "location_summary": "Long Beach, California",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03872596"
    },
    {
      "nct_id": "NCT01404806",
      "title": "GSK1349572 Exposure in Blood, Cervicovaginal Fluid, and Cervical and Vaginal Tissue in Healthy Female Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Adult Females"
      ],
      "interventions": [
        {
          "name": "GSK1349572 (dolutegravir)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 35 Years · Female only"
      },
      "enrollment_count": 10,
      "start_date": "2011-08",
      "completion_date": "2012-09",
      "has_results": false,
      "last_update_posted_date": "2013-07-04",
      "last_synced_at": "2026-10-06T11:33:57.780Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01404806"
    },
    {
      "nct_id": "NCT03186781",
      "title": "Influenza HA Ferritin Vaccine, Alone or in Prime-Boost Regimens With an Influenza DNA Vaccine in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "VRC-FLUNPF081-00-VP (HA-F A/Sing)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "VRC-FLUDNA082-00-VP (DNA A/Sing)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 50,
      "start_date": "2017-10-25",
      "completion_date": "2019-09-03",
      "has_results": true,
      "last_update_posted_date": "2021-06-16",
      "last_synced_at": "2026-10-06T11:33:57.780Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03186781"
    },
    {
      "nct_id": "NCT02859129",
      "title": "Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hypertriglyceridemia"
      ],
      "interventions": [
        {
          "name": "rosuvastatin 40 mg tablet",
          "type": "DRUG"
        },
        {
          "name": "Epanova™ QD (2 x 1 g capsules)",
          "type": "DRUG"
        },
        {
          "name": "Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose",
          "type": "DRUG"
        },
        {
          "name": "Multiple (20) oral doses of 2 g Vascepa® every 12 hours",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 114,
      "start_date": "2013-09",
      "completion_date": "2013-11",
      "has_results": false,
      "last_update_posted_date": "2016-08-17",
      "last_synced_at": "2026-10-06T11:33:57.780Z",
      "location_count": 1,
      "location_summary": "Neptune City, New Jersey",
      "locations": [
        {
          "city": "Neptune City",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02859129"
    },
    {
      "nct_id": "NCT02579707",
      "title": "Food Effect Study of AG120 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "AG120",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Agios Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 36,
      "start_date": "2015-10",
      "completion_date": "2016-06",
      "has_results": false,
      "last_update_posted_date": "2016-11-29",
      "last_synced_at": "2026-10-06T11:33:57.780Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02579707"
    },
    {
      "nct_id": "NCT07501039",
      "title": "A Phase 1 Study of BLKR201 in Healthy Adult Participants",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "BLKR201",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Formation Bio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 128,
      "start_date": "2026-04-27",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-10-06T11:33:57.780Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07501039"
    },
    {
      "nct_id": "NCT05888207",
      "title": "A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Male Subjects"
      ],
      "interventions": [
        {
          "name": "Savolitinib",
          "type": "DRUG"
        },
        {
          "name": "Fluvoxamine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 16,
      "start_date": "2023-06-02",
      "completion_date": "2023-08-17",
      "has_results": false,
      "last_update_posted_date": "2023-08-29",
      "last_synced_at": "2026-10-06T11:33:57.780Z",
      "location_count": 1,
      "location_summary": "Brooklyn, Maryland",
      "locations": [
        {
          "city": "Brooklyn",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05888207"
    }
  ]
}